Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Capitol Capsule: Could another biosimilars fight be a brewin'?

This article was originally published in Scrip

Executive Summary

There was hardly time to yawn at the US FDA's unusually short 16 December meeting to discuss its proposed recommendations for a biosimilars user fee programme, with a handful of industry and other stakeholders getting straight to the point with their mostly anticipated comments and few questions raised by regulators at the less than two hour public event. But Christopher Ohly, a partner at the Washington law firm Schiff Hardin, predicted there's potentially a fight a brewin' based on comments made at the meeting unrelated to the user fees.

Advertisement

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC015599

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel